Fresolimumab Biosimilar - Research Grade

Human

TGF beta 1

>1mg/ml

Human IgG4 S228P Kappa

Linavonkibart Biosimilar - Research Grade (ICH5253), Metelimumab Biosimilar - Research Grade (ICH5257), Cirevetmab Biosimilar - Research Grade (ICH5440), Nisevokitug Biosimilar - Research Grade (ICH5713)

https://www.imgt.org/mAb-DB/

ICH3002

P01137

7040

RRID:AB_2921619

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of fresolimumab, supplied strictly for research use only. It is not the clinical drug and is not intended for human or veterinary use. Fresolimumab is a human IgG4 (S228P-stabilized) antibody originally developed to neutralize transforming growth factor beta, and this research-grade analog is built around the same TGF-beta 1 target (UniProt P01137) to reproduce that binding and neutralizing behavior in the laboratory. Because it is offered as a bulk, low-endotoxin reagent (research grade under 1 EU/mg, with ultra-low-endotoxin under 0.5 EU/mg options), it is well suited to work requiring larger antibody quantities and reproducible lots: positive and isotype-matched controls, ligand-neutralization assays, receptor-blockade studies, ADCC/ADC development workflows, and preclinical in-vitro and in-vivo model systems. The S228P hinge mutation reduces IgG4 half-antibody exchange for lot stability. It supplies a consistent, well-defined tool for interrogating TGF-beta 1 signaling without the constraints or cost of clinical-grade material. TGF-beta 1, encoded by TGFB1, is a secreted multifunctional cytokine and the prototypical member of the transforming growth factor beta superfamily. It is produced as a latent complex: the mature growth factor remains non-covalently associated with its latency-associated peptide until activated by integrins, proteases, or mechanical force. Active TGF-beta 1 signals through the type II and type I (ALK5) serine/threonine kinase receptors, driving SMAD2/3 phosphorylation and transcriptional programs, alongside non-canonical pathways. It is a master regulator of cell proliferation, differentiation, extracellular matrix deposition, epithelial-to-mesenchymal transition, and immune tolerance, including regulatory T-cell induction and suppression of effector lymphocytes. Dysregulated TGF-beta 1 signaling contributes to tissue fibrosis, tumor immune evasion, and metastasis, making it a prominent target in oncology and fibrotic disease research.

Transforming growth factor beta-1 proprotein, TGFB1, TGFB

Detects human TGFbeta1. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Fresolimumab.

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

S228P

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Fresolimumab (anti-TGF beta 1) Biosimilar

Q: Is the Fresolimumab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Fresolimumab suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Fresolimumab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Fresolimumab that binds human TGF beta 1.